Clinical trial Recruiting at 1 site Interventional Ages 6 to 14

Bedtime device restriction plus desmopressin for bedwetting in kids

Official title: Effect of Bedtime Digital-Device Restriction on the Therapeutic Response to Desmopressin in Children With Primary Monosymptomatic Nocturnal Enuresis: A Randomized Controlled Trial

Run by Al-Azhar University · NCT07776977 · Data updated 2026-11-12

This trial tests whether limiting screen time at night helps desmopressin work better for children with primary monosymptomatic nocturnal enuresis.

Quick facts

Study typeInterventional
Ages6 Years to 14 Years
SexAll
Enrollment140 (estimated)
SponsorAl-Azhar University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedAugust 20, 2026
Main results expectedMay 2027
Study endsJuly 2027
Registry record updatedAugust 24, 2026
Trial IDNCT07776977 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children aged 6–14 with primary monosymptomatic nocturnal enuresis, willing to take desmopressin nightly for 8 weeks, and whose guardians can monitor screen time and wet nights.

Probably not a fit

Some participants may not respond to desmopressin or derive additional benefit from restricting bedtime screens.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, open-label, randomized trial in Cairo, Egypt, enrolling 6- to 14-year-olds with primary monosymptomatic nocturnal enuresis. Participants are randomly assigned to receive desmopressin for 8 weeks with either bedtime digital-device restriction (at least 60 minutes before bed) or usual screen use, alongside standard clinical follow-up and dose adjustment. The study will measure the proportion with a full response (no more than one wet night in the last two weeks) and secondary outcomes such as weekly wet nights, partial response, sleep quality, adherence, and relapse four weeks after treatment ends. Baseline data will be collected to identify predictors of response. Outcomes will help determine if behavior modification around screen time enhances pharmacologic treatment.

Why it matters

Potential benefit: If successful, children may achieve better nighttime dryness with a simple behavioral change in addition to medication.

How similar studies have gone: Past studies have shown that behavioral factors can influence enuresis outcomes, but this specific combination with bedtime device restriction is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 6-14 years.
* Diagnosis of PMNE (≥2 wet nights/week for ≥6 months, no daytime symptoms, no prior sustained dryness \>6 months).
* Willingness to take oral desmopressin nightly for 8 weeks.
* Parent/guardian able to monitor and report screen time and wet nights.
* Written informed consent from parent/guardian and assent from child (if age-appropriate).

Exclusion Criteria:

* Secondary enuresis or non-monosymptomatic enuresis (daytime incontinence, urgency, frequency).
* Known organic causes (e.g., diabetes mellitus, urinary tract anomalies, neurological disorders).
* Current use of other enuresis treatments (alarms, anticholinergics, imipramine) within 4 weeks prior to enrollment.
* Severe sleep disorders (e.g., obstructive sleep apnea) or psychiatric conditions affecting compliance.
* Inability to comply with study procedures or follow-up.

Where it's running

  • Department of Urology, Al-Hussein and Sayed Galal University Hospitals, Al-Azhar University
    Cairo, Egypt
    Recruiting

Study contacts

  • Principal investigator: Abul-fotouh Ahmed — Department of Urology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
  • Study coordinator: Abul-fotouh Ahmed
  • Email: abulfotouhahmed@yahoo.com
  • Phone: +201001066756

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.